SCHEMBL13879738

SCHEMBL13879738

CNc1cncc(NCc2ccc(CNc3nccc(C(F)(F)F)n3)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
PKM P14618 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SYK P43405 1/20 0.40
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
GPR39 O43194 2/20 0.38
GNRHR P30968 1/20 0.37
PTGS2 P35354 1/20 0.37
PLK1 P53350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879819 0.83 PKM (0.52) KDM4EHSD17B10MEN1HTTKMT2A
SCHEMBL13879795 0.77 KDM4E (0.50) KDM4EHSD17B10MEN1HTTKMT2A
SCHEMBL3265212 0.72 SYK (0.49) MEN1KMT2AATMPKMALDH1A1
SCHEMBL8350149 0.71 PKM (0.52) KDM4EHTTATMPKMHPGD
SCHEMBL13891924 0.71 KDM4E (0.41) KDM4EHSD17B10MEN1HTTKMT2A
SCHEMBL14310598 0.70 PKM (0.59) KDM4EPKMSYKMAPTPLK1
SCHEMBL13879821 0.70 CXCR4 (0.54) KDM4EHSD17B10MEN1HTTKMT2A
SCHEMBL12932877 0.68 HRH4 (0.50) KDM4EPKMSYKMAPTPLK1
SCHEMBL12963477 0.68 PKM (0.57) KDM4EPKMSYKMAPTPTGS2
SCHEMBL13891925 0.68 SYK (0.47) KDM4EHSD17B10MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8080659-B2 CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders EMORY UNIVERSITY (US) 2011-12-20 US disclosed
US-8080659-B2 CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders EMORY UNIVERSITY (US) 2011-12-20 US disclosed
US-20090099194-A1 CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders EMORY UNIVERSITY 2009-04-16 US disclosed
US-20090099194-A1 CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders EMORY UNIVERSITY 2009-04-16 US disclosed
WO-2008008854-A9 CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS UNIV EMORY (US) 2008-03-27 WO disclosed
WO-2008008854-A2 CXCR4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS EMORY UNIVERSITY (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099194-A1 CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders CXCR4, CXCL12, CCR5 KDM4E 3897/4885HSD17B10 3915/4885MEN1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.